国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2012年
9期
1248-1250
,共3页
糖尿病肾病%残存肾功能%中西医治疗
糖尿病腎病%殘存腎功能%中西醫治療
당뇨병신병%잔존신공능%중서의치료
Diabetic nephropathy%Residual renal function%Therapy with traditional Chinese and Western medicine
目的 探讨2型糖尿病肾病Ⅲ期患者残存肾功能的保护方法.方法 选择2型糖尿病肾病Ⅲ期患者70例,将其随机分为观察组38例和对照组32例；观察组给予贝那普利合用益肾固精活血中药煎剂治疗,对照组单用盐酸贝那普利片治疗.结果 观察组治疗前后以及治疗后观察组与对照组半胱氨酸蛋白酶抑制剂C水平比较差异均有显著[前者:(1.62±0.59) mg/L vs.(1.29±0.38) mg/L,t=2.899,P=0.005;后者:( 1.29±0.38) mg/L vs.( 1.51±0.43) mg/L,t=2.272,P=0.026].两组肾脏生存曲线无交叉,观察组肾脏生存率(92.1％)优于对照组肾脏生存率(75.0％)(Log-rank检验,x2=4.227,P=0.040).结论 贝那普利合用益肾固精活血中药治疗对2型糖尿病肾病Ⅲ期患者残存肾功能可能有更好的保护作用.
目的 探討2型糖尿病腎病Ⅲ期患者殘存腎功能的保護方法.方法 選擇2型糖尿病腎病Ⅲ期患者70例,將其隨機分為觀察組38例和對照組32例；觀察組給予貝那普利閤用益腎固精活血中藥煎劑治療,對照組單用鹽痠貝那普利片治療.結果 觀察組治療前後以及治療後觀察組與對照組半胱氨痠蛋白酶抑製劑C水平比較差異均有顯著[前者:(1.62±0.59) mg/L vs.(1.29±0.38) mg/L,t=2.899,P=0.005;後者:( 1.29±0.38) mg/L vs.( 1.51±0.43) mg/L,t=2.272,P=0.026].兩組腎髒生存麯線無交扠,觀察組腎髒生存率(92.1％)優于對照組腎髒生存率(75.0％)(Log-rank檢驗,x2=4.227,P=0.040).結論 貝那普利閤用益腎固精活血中藥治療對2型糖尿病腎病Ⅲ期患者殘存腎功能可能有更好的保護作用.
목적 탐토2형당뇨병신병Ⅲ기환자잔존신공능적보호방법.방법 선택2형당뇨병신병Ⅲ기환자70례,장기수궤분위관찰조38례화대조조32례；관찰조급여패나보리합용익신고정활혈중약전제치료,대조조단용염산패나보리편치료.결과 관찰조치료전후이급치료후관찰조여대조조반광안산단백매억제제C수평비교차이균유현저[전자:(1.62±0.59) mg/L vs.(1.29±0.38) mg/L,t=2.899,P=0.005;후자:( 1.29±0.38) mg/L vs.( 1.51±0.43) mg/L,t=2.272,P=0.026].량조신장생존곡선무교차,관찰조신장생존솔(92.1％)우우대조조신장생존솔(75.0％)(Log-rank검험,x2=4.227,P=0.040).결론 패나보리합용익신고정활혈중약치료대2형당뇨병신병Ⅲ기환자잔존신공능가능유경호적보호작용.
Objective To explore the protective method of residual renal function in patients with stage Ⅲ type 2 diabetic nephropathy.Methods 70 patients with stage Ⅲ type 2 diabetic nephropathy were randomly divided into study group ( 38 patients ) and control group ( 32 patients ).The study group received benazepril combining with Chinese therapy with Yishen Gujing Huoxue,and the control group received benazepril alone.Results There was a significant difference in cystatin C levels between pre-treatment and post-treatment in the study group [( 1.62 ± 0.59 )mg/L vs.( 1.29 ± 0.38 ) mg/L,t =2.899,and P=0.005] and cystatin C levels differed significantly between the study group and the control group after treatment [( 1.29 ± 0.38 ) mg/L vs.( 1.51 ± 0.43 ) mg/L,t =2.272,and P=0.026].The renal survival curve did not cross between the two groups.The study group was superior to the control group in renal survival rate (92.1％vs.75％, Log-rank test:x2=4.227, P=0.040).Conclusions Benazepril combining with Chinese therapy with Yishen Gujing Huoxue may play a better role in the protection of residual renal function in patients with stage Ⅲ type 2 diabetic nephropathy.
